



## **Fate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference**

SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2017 Piper Jaffray Healthcare Conference in New York on Tuesday, November 28, 2017 at 12:50 p.m. ET.

A live webcast of the presentation will be available through the investor relations section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). Following the live webcast, an archived replay will be available on the Company's website.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel *ex vivo* cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

### **Contact:**

Christina Tartaglia  
Stern Investor Relations, Inc.  
212.362.1200  
[christina@sternir.com](mailto:christina@sternir.com)